NewLink will also receive royalties from Merck, according to the report.
The experimental vaccine rVSV-EBOV was originally developed by the Public Health Agency of Canada, which will retain non-commercial rights to it.
Merck will take over vaccine development and any additional related products. The pharmaceutical company has said large-scale trials of the vaccine could begin early next year, according to the report.
The vaccine is currently undergoing early-stage trials, which test the vaccine on healthy volunteers to determine if it is safe and initiate a protective immune response, according to the report. If the results of this trial are positive, then larger late-stage trials can begin.
More articles on Ebola:
ECRI Institute creates Ebola PPE price index
Able and ready: America’s hospitals and the false threat of Ebola
New York woman’s remains test negative for Ebola
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.